Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid
All three companies are developing drugs made up of a shortened version of the dystrophin gene, which normally protects muscle cells but is absent in boys with Duchenne.
U.S. Markets open in 1 hr 14 mins
S&P Futures
2,705.50-4.25(-0.16%)Dow Futures
24,709.00-24.00(-0.10%)Nasdaq Futures
6,829.25-14.25(-0.21%)Russell 2000
1,583.56+3.76(+0.24%)Crude Oil
69.40+0.93(+1.36%)Gold
1,351.70-1.80(-0.13%)Silver
17.25+0.01(+0.04%)EUR/USD
1.24+0.00(+0.02%)
Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid
American City Business Journals•